SL
Silence Therapeutics plc
SLN · NASDAQ
$13.55 -0.99% (-$0.13)
1M -7.95%
Market Cap $640.0M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 1,041.88x
P/B 16.64x
P/E N/A
Growth
22 /100
Declining Rev. growth 68.36%
Book val. growth 41.33%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.00%
Net margin 9,755.61%
Op. margin 11,003.00%
Quality
0 /100
Poor ROIC 176.21%
ROE 106.90%
ROA 56.32%
Debt
33 /100
High Debt/Equity -0.00x
Current ratio 7.42x
Int. coverage N/A
Stability
41 /100
Moderate Beta 1.41x
Rev. volatility 90.95%
EPS volatility 11.98%
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report